Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Gains from Sales and Divestitures (2017 - 2025)

Aptevo Therapeutics (APVO) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $26.0 as the latest value for Q3 2025.

  • Quarterly Gains from Sales and Divestitures fell 99.21% to $26.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $26.0 through Sep 2025, down 99.21% year-over-year, with the annual reading at $117.0 for FY2024, 99.88% down from the prior year.
  • Gains from Sales and Divestitures hit $26.0 in Q3 2025 for Aptevo Therapeutics, down from $72.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $101504.0 in Q4 2023 to a low of $26.0 in Q3 2025.
  • Historically, Gains from Sales and Divestitures has averaged $24374.9 across 5 years, with a median of $10582.0 in 2022.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 1690.3% in 2022 and later plummeted 99.88% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $1000.0 in 2021, then soared by 1690.3% to $17903.0 in 2022, then skyrocketed by 466.97% to $101504.0 in 2023, then tumbled by 99.88% to $117.0 in 2024, then plummeted by 77.78% to $26.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for APVO at $26.0 in Q3 2025, $72.0 in Q1 2025, and $117.0 in Q4 2024.